注意，600165要大幅除权了！

Core Viewpoint - *ST Ningke has finalized the details of its capital reserve stock increase plan, which involves a total of 931 million shares being issued, significantly increasing its total share capital from 685 million to 1.616 billion shares [4][11]. Group 1: Stock Increase Details - The stock increase consists of 883 million shares for introducing restructuring investors, raising approximately 1.241 billion yuan in cash, and 48 million shares for debt compensation, amounting to about 576 million yuan [2][13]. - The new controlling shareholder, Hunan Xinhai New Biological Pharmaceutical Co., Ltd., will hold a 22.10% stake in the company post-increase [2][10]. Group 2: Stock Trading Information - The stock will be suspended for one trading day on the registration date, December 10, and will resume trading on December 11, with an ex-rights reference price set at 2.84 yuan per share [5][7]. - The average price for the capital reserve stock increase is calculated to be 1.95 yuan per share, leading to a downward adjustment of the opening reference price on December 11 [7]. Group 3: Restructuring and Financial Health - The restructuring plan includes a commitment from the investors for a lock-up period of 36 months for industrial investors and 12 months for financial investors [8]. - As of the end of 2023, Hunan Xinhai New has total assets of 3.512 billion yuan and revenue of 1.236 billion yuan, focusing on the research, production, and sales of steroid intermediates and raw materials [14].